Anna Persson1, Sudie E Back, Therese K Killeen, Kathleen T Brady, Melanie L Schwandt, Markus Heilig, Åsa Magnusson. 1. Department of Clinical Neuroscience (AP, AM), Karolinska Institutet; EWA Outpatient Unit (AP, AM), The Stockholm Centre for Dependency Disorders, Stockholm, Sweden; Department of Psychiatry (SEB, TKK, KTB), Medical University of South Carolina; Ralph H. Johnson Veterans Affairs (VA) Medical Center (SEB, KTB), Charleston, SC; Laboratory of Clinical and Experimental Studies (MLS), NIAAA, Bethesda, MD; Department of Clinical and Experimental Medicine (MH), Linköping University, Linköping, Sweden.
Abstract
OBJECTIVES: Posttraumatic stress disorder (PTSD) and substance use disorders are highly comorbid. Effective treatments are largely lacking. This pilot study evaluated the safety and feasibility of a novel intervention, Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE), in preparation for a randomized controlled trial. METHODS:Twenty-two treatment-seeking women with current DSM-IV-TR PTSD and alcohol dependence (AD) were recruited. Participants received COPE. Safety and feasibility were evaluated, as were efficacy-related outcomes: PTSD and depression symptom severity, alcohol use, craving, and dependence severity. RESULTS: No adverse events occurred. COPE was implemented in routine clinical practice. Among the assessed women, 95.8% were eligible to participate. Treatment attendance and completion were higher than in previous studies. Post treatment, all efficacy-related outcomes, including PTSD and depression symptom severity, alcohol use, craving, and dependence severity, were significantly reduced. CONCLUSIONS:COPE was safe and feasible to use. Concerns that trauma-focused, exposure-based therapy might promote relapse in this population appear unwarranted. Our findings provide initial evidence suggestive of COPE efficacy for comorbid PTSD and AD in women. These results provide a strong rationale for investigating the efficacy of COPE for comorbid PTSD and AD in women in a randomized controlled trial.
RCT Entities:
OBJECTIVES:Posttraumatic stress disorder (PTSD) and substance use disorders are highly comorbid. Effective treatments are largely lacking. This pilot study evaluated the safety and feasibility of a novel intervention, Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE), in preparation for a randomized controlled trial. METHODS: Twenty-two treatment-seeking women with current DSM-IV-TR PTSD and alcohol dependence (AD) were recruited. Participants received COPE. Safety and feasibility were evaluated, as were efficacy-related outcomes: PTSD and depression symptom severity, alcohol use, craving, and dependence severity. RESULTS: No adverse events occurred. COPE was implemented in routine clinical practice. Among the assessed women, 95.8% were eligible to participate. Treatment attendance and completion were higher than in previous studies. Post treatment, all efficacy-related outcomes, including PTSD and depression symptom severity, alcohol use, craving, and dependence severity, were significantly reduced. CONCLUSIONS: COPE was safe and feasible to use. Concerns that trauma-focused, exposure-based therapy might promote relapse in this population appear unwarranted. Our findings provide initial evidence suggestive of COPE efficacy for comorbid PTSD and AD in women. These results provide a strong rationale for investigating the efficacy of COPE for comorbid PTSD and AD in women in a randomized controlled trial.
Authors: Anna Kline; Marc D Weiner; Donald S Ciccone; Alejandro Interian; Lauren St Hill; Miklos Losonczy Journal: J Psychiatr Res Date: 2013-12-01 Impact factor: 4.791
Authors: David S Riggs; Margaret Rukstalis; Joseph R Volpicelli; Danielle Kalmanson; Edna B Foa Journal: Addict Behav Date: 2003-12 Impact factor: 3.913
Authors: Sudie E Back; Therese Killeen; Christal L Badour; Julianne C Flanagan; Nicholas P Allan; Elizabeth Santa Ana; Brian Lozano; Kristina J Korte; Edna B Foa; Kathleen T Brady Journal: Addict Behav Date: 2018-11-27 Impact factor: 3.913
Authors: Sonya B Norman; Ryan Trim; Moira Haller; Brittany C Davis; Ursula S Myers; Peter J Colvonen; Erika Blanes; Robert Lyons; Emma Y Siegel; Abigail C Angkaw; Gregory J Norman; Tina Mayes Journal: JAMA Psychiatry Date: 2019-08-01 Impact factor: 21.596
Authors: Cynthia L Lancaster; Daniel F Gros; Michael C Mullarkey; Christal L Badour; Therese K Killeen; Kathleen T Brady; Sudie E Back Journal: Behav Cogn Psychother Date: 2019-04-23
Authors: Christal L Badour; Julianne C Flanagan; Nicholas P Allan; Amanda K Gilmore; Daniel F Gros; Therese Killeen; Kristina J Korte; Delisa G Brown; Kateryna Kolnogorova; Sudie E Back Journal: J Trauma Stress Date: 2021-11-13
Authors: Ashton E Clark; Shelby R Goodwin; Russell M Marks; Annabelle M Belcher; Emily Heinlein; Melanie E Bennett; Daniel J O Roche Journal: J Dual Diagn Date: 2021-09-28